Navidea Biopharmaceuticals Inc (NAVB)

0.52
0.00 0.94
AMEX : Health Care
Prev Close 0.52
Open 0.53
Day Low/High 0.51 / 0.53
52 Wk Low/High 0.47 / 2.50
Volume 243.88K
Avg Volume 1.10M
Exchange AMEX
Shares Outstanding 155.61M
Market Cap 80.92M
EPS -0.20
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Navidea To Provide Shareholder Update

Navidea To Provide Shareholder Update

Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) announces a conference call on Wednesday, June 15, 2016 at 5:00 p.

Navidea Announces Data Presentations At 2016 Annual Meeting Of The Society Of Nuclear Medicine And Molecular Imaging (SNMMI)

Navidea Announces Data Presentations At 2016 Annual Meeting Of The Society Of Nuclear Medicine And Molecular Imaging (SNMMI)

Navidea Biopharmaceuticals, Inc. (NYSE MKT:NAVB), today announced that results from investigator studies using Lymphoseek ® (technetium Tc 99m tilmanocept) injection are being presented at the 2016 Annual Meeting of...

$1.8 Million Fast-Track NIH SBIR Grant For Manocept™ Immunotherapeutics Evaluation In Kaposi's Sarcoma Awarded To Navidea

$1.8 Million Fast-Track NIH SBIR Grant For Manocept™ Immunotherapeutics Evaluation In Kaposi's Sarcoma Awarded To Navidea

Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) announces the receipt of an initial notice of award for a Fast- track Small Business Innovation Research (SBIR) grant providing for up to $1.

Navidea Provides Financing Update

Navidea Provides Financing Update

Navidea Biopharmaceuticals, Inc. (NYSE MKT:NAVB), today announced that it has received an unsolicited offer to refinance the entire existing CRG loan facility.

Navidea Reports First Quarter 2016 Financial Results

Navidea Reports First Quarter 2016 Financial Results

Navidea Biopharmaceuticals, Inc. (NYSE MKT:NAVB), today announced financial results for the first quarter of 2016.

Navidea Biopharmaceuticals To Announce First Quarter 2016 Financial Results On May 17, 2016

Navidea Biopharmaceuticals To Announce First Quarter 2016 Financial Results On May 17, 2016

Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) today announced that the Company will report its financial results for the first quarter 2016, on Tuesday, May 17, 2016 prior to a conference call with the investment...

Navidea And Macrophage Therapeutics To Provide Development Program Update

Navidea And Macrophage Therapeutics To Provide Development Program Update

Navidea Biopharmaceuticals, Inc. (NYSE MKT:NAVB) announces a conference call on Thursday, May 5, 2016 at 4:30 p.

Navidea Appoints Jed Latkin As Interim Chief Operating Officer

Navidea Appoints Jed Latkin As Interim Chief Operating Officer

Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), announced today that Jed A.

Navidea And Macrophage Therapeutics To Provide Business Update

Navidea And Macrophage Therapeutics To Provide Business Update

Navidea Biopharmaceuticals, Inc. (NYSE MKT:NAVB) announces a conference call on Monday, April 18, 2016 at 4:30 p.

Navidea Updates Clinical Development Plan For Diagnostic Use Of Lymphoseek® IV In Rheumatoid Arthritis

Navidea Updates Clinical Development Plan For Diagnostic Use Of Lymphoseek® IV In Rheumatoid Arthritis

Navidea Biopharmaceuticals, Inc. (NYSE MKT:NAVB) announced today that based on its very recent meeting with the U.

Navidea Announces Fourth Quarter And Full Year 2015 Results

Navidea Announces Fourth Quarter And Full Year 2015 Results

Navidea Biopharmaceuticals, Inc. (NYSE MKT:NAVB), today announced results for the fourth quarter and year ended December 31, 2015.

Navidea Biopharmaceuticals To Announce Fourth Quarter And Full Year 2015 Results On March 23, 2016

Navidea Biopharmaceuticals To Announce Fourth Quarter And Full Year 2015 Results On March 23, 2016

Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) today announced that the Company will report its financial results for the fourth quarter and full-year 2015, on Wednesday, March 23, 2016 prior to a conference call with...

Navidea Biopharmaceuticals Announces Delay In Filing Of Form 10-K

Navidea Biopharmaceuticals Announces Delay In Filing Of Form 10-K

Navidea Biopharmaceuticals (NYSE MKT:NAVB) ("Navidea" or the "Company") announced today that it will be filing a Form 12b-25, Notification of Late Filing, with the Securities and Exchange Commission (the "SEC"), extending...

Navidea And Platinum Enter Into Agreement Reaffirming Loan Obligations And Agreeing To Standstill Provisions

Navidea And Platinum Enter Into Agreement Reaffirming Loan Obligations And Agreeing To Standstill Provisions

Navidea Biopharmaceuticals, Inc. (NYSE MKT:NAVB) ("Navidea" or the "Company") announced today that Navidea and Platinum Management (NY) LLC and certain of its affiliated individuals and entities (referred to in this press...

Reprint Of Navidea Article From March Issue Of Nuclear Medicine And Biology

Reprint Of Navidea Article From March Issue Of Nuclear Medicine And Biology

Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), announced a publication in Nuclear Medicine and Biology, the official journal of the Society of Radiopharmaceutical Sciences, which describes the clinical linkage between...

Navidea Biopharmaceuticals Enrolls First Patient In Cervical Cancer Study Of Lymphoseek®

Navidea Biopharmaceuticals Enrolls First Patient In Cervical Cancer Study Of Lymphoseek®

Navidea Biopharmaceuticals, Inc. (NYSE MKT:NAVB), today announced that the first patient has been enrolled in a clinical study evaluating Lymphoseek ® (technetium Tc 99m tilmanocept) injection in women with known...

Navidea Biopharmaceuticals To Present At 2016 BIO CEO & Investor Conference

Navidea Biopharmaceuticals To Present At 2016 BIO CEO & Investor Conference

Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), announces that Rick Gonzalez, President and Chief Executive Officer, will present a corporate overview on Monday, February 8, 2016 at 1:00 PM ET at the 2016 BIO CEO &...

Navidea Provides Update On Lymphoseek® And Immunodiagnostics Development Pipeline

Navidea Provides Update On Lymphoseek® And Immunodiagnostics Development Pipeline

Navidea Biopharmaceuticals, Inc. (NYSE MKT:NAVB), today provides an update on its commercial and clinical development efforts with respect to its Lymphoseek ® (technetium Tc 99m tilmanocept) injection, the first and...

Navidea Issues Letter To Shareholders With Corporate Update.

Navidea Issues Letter To Shareholders With Corporate Update.

Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), today reports 2015 preliminary unaudited Lymphoseek ® (technetium Tc 99m tilmanocept) injection sales of $10.

Navidea Appoints Anton Gueth Chairman Of The Board

Navidea Appoints Anton Gueth Chairman Of The Board

Navidea Biopharmaceuticals, Inc. (NYSE MKT:NAVB), announced that its Board of Directors has appointed board member Anton Gueth to the position of Chairman.

Navidea Biopharmaceuticals Enrolls First Patient In Pediatric Trial Of Lymphoseek®

Navidea Biopharmaceuticals Enrolls First Patient In Pediatric Trial Of Lymphoseek®

Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), today announced that the first pediatric patient was enrolled in a clinical study comparing Lymphoseek ® (technetium Tc 99m tilmanocept) injection and vital blue dye...

Navidea Biopharmaceuticals To Present At Biotech Showcase 2016

Navidea Biopharmaceuticals To Present At Biotech Showcase 2016

Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) announced that Rick Gonzalez, President and Chief Executive Officer, will present at the Biotech Showcase 2016, taking place in San Francisco, CA, on Tuesday, January 12th...

Lymphoseek® Technically Successful In Evaluation Of Sentinel Lymph Node Biopsy In Patients Undergoing Neoadjuvant Chemotherapy

Lymphoseek® Technically Successful In Evaluation Of Sentinel Lymph Node Biopsy In Patients Undergoing Neoadjuvant Chemotherapy

Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) today announced that results from an investigator-initiated retrospective analysis demonstrated Lymphoseek ® (technetium Tc 99m tilmanocept) injection was successful in...

Lymphoseek® Reduces Sentinel Lymph Node Biopsy Imaging Time, Facilitating Patient Throughput And Workflow Efficiencies

Lymphoseek® Reduces Sentinel Lymph Node Biopsy Imaging Time, Facilitating Patient Throughput And Workflow Efficiencies

Navidea Biopharmaceuticals, Inc. (NYSE MKT:NAVB) today announced that results from an investigator-initiated imaging study demonstrated Lymphoseek ® (technetium Tc 99m tilmanocept) injection reduced imaging time by...

Navidea Biopharmaceuticals To Present At Stifel 2015 Healthcare Conference

Navidea Biopharmaceuticals To Present At Stifel 2015 Healthcare Conference

Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), announces that Rick Gonzalez, President and Chief Executive Officer, will present a corporate overview on Wednesday, November 18, 2015 at 3:00 PM ET at the Stifel 2015...

Insider Trading Alert - EAT, NAVB And INTC Traded By Insiders

Insider Trading Alert - EAT, NAVB And INTC Traded By Insiders

Stocks with insider trader activity include EAT, NAVB and INTC

Navidea Reports 2015 Third Quarter Financial Results

Navidea Reports 2015 Third Quarter Financial Results

Navidea Biopharmaceuticals (NYSE MKT:NAVB) reports financial results for the quarter ending September 30, 2015.

NAVB: Insiders vs. Shorts

NAVB: Insiders vs. Shorts

The most recent short interest data was recently released by the NASDAQ for the 09/30/2015 settlement date, and Navidea Biopharmaceuticals, Inc. is one of the most shorted stocks of the Russell 3000, based on 21.20 "days to cover" versus the median component at 5.50.